We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
-1.48%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$105M
AUM Growth
+$13.8M
Cap. Flow
+$17.8M
Cap. Flow %
16.98%
Top 10 Hldgs %
80.95%
Holding
24
New
6
Increased
8
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.26M
3
TDOC icon
Teladoc Health
TDOC
+$4.55M
4
ABBV icon
AbbVie
ABBV
+$3.62M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.51M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$9.54M
2
AMGN icon
Amgen
AMGN
+$7.78M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$5.31M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.7M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Industrials 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$454B
$13M 12.38%
148,439
+38,439
+35% +$3.62M
BMY icon
2
Bristol-Myers Squibb
BMY
$126B
$12.9M 12.25%
213,314
+41,821
+24% +$2.52M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.4B
$12.6M 11.97%
165,181
+115,292
+231% +$11.7M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$120B
$12.2M 11.66%
44,989
+22,684
+102% +$6.26M
ARNA
5
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$6.4M 6.09%
+85,537
New +$5.7M
IQV icon
6
IQVIA
IQV
$34.6B
$6.22M 5.92%
39,432
-568
-1% -$89K
FATE icon
7
Fate Therapeutics
FATE
$294M
$6.13M 5.84%
153,297
-2,208
-1% -$77.1K
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.75M 5.48%
42,186
-14,814
-26% -$1.58M
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.11M 4.87%
52,488
+30,488
+139% +$3.51M
TDOC icon
10
Teladoc Health
TDOC
$1.56B
$4.71M 4.49%
+21,500
New +$4.55M
TBIO
11
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$3.1M 2.95%
227,719
+137,719
+153% +$2.12M
RCUS icon
12
Arcus Biosciences
RCUS
$3.74B
$2.95M 2.81%
171,982
+47,578
+38% +$1.06M
RVMD icon
13
Revolution Medicines
RVMD
$40.1B
$2.82M 2.69%
+81,000
New +$2.24M
NBIX icon
14
Neurocrine Biosciences
NBIX
$17.5B
$2.69M 2.56%
+28,000
New +$3.24M
TGTX icon
15
TG Therapeutics
TGTX
$8.5B
$2.54M 2.42%
+95,000
New +$2.19M
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$2.02M 1.92%
278,416
-8,584
-3% -$45.9K
ACCD
17
DELISTED
Accolade Inc
ACCD
$1.94M 1.85%
+50,000
New +$1.72M
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.94M 1.85%
7,938
+1,271
+19% +$395K
AMGN icon
19
Amgen
AMGN
$201B
– –
-33,000
Closed -$7.78M
OSUR icon
20
OraSure Technologies
OSUR
$277M
– –
-78,875
Closed -$917K
ARNA
21
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-79,672
Closed -$5.31M
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-85,000
Closed -$9.54M
MNTA
23
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-88,000
Closed -$2.93M
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-84,626
Closed -$4.7M

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Copernicus Capital Management held 24 positions worth $105M, up 15% from $91.2M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Copernicus Capital Management deployed $17.8M of net new capital in Q3 2020, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Teladoc Health: 21,500 shares worth $4.71M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was MyoKardia, Inc. Common Stock, an estimated $1.58M trimmed.

  • Copernicus Capital Management's largest Q3 2020 buy was Teladoc Health: 21,500 shares worth $4.71M.
  • Copernicus Capital Management added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $11.7M increase.
  • Copernicus Capital Management's biggest Q3 2020 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $1.58M.
  • Copernicus Capital Management fully exited Alexion Pharmaceuticals in Q3 2020, selling an estimated $9.54M.
  • Copernicus Capital Management's ten largest holdings make up 81% of its $105M portfolio in Q3 2020.
  • Copernicus Capital Management opened 6 new positions and closed 6 in Q3 2020.
  • Copernicus Capital Management's portfolio value rose 15% quarter-over-quarter to $105M.

Based on Copernicus Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.